La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Acarix Bilan de santé

Santé financière contrôle des critères 6/6

Acarix possède un total de capitaux propres de SEK84.7M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK95.8M et de SEK11.1M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 48.27m
Fonds propres	SEK 67.81m
Total du passif	SEK 11.81m
Total des actifs	SEK 79.62m

Mises à jour récentes de la santé financière

Recent updates

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Jun 13

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

Jun 12

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Oct 27

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Jun 22

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

Mar 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ACARIX ( SEK83.6M ) dépassent ses passifs à court terme ( SEK11.1M ).

Passif à long terme: ACARIX n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: ACARIX est sans dette.

Réduire la dette: ACARIX n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ACARIX dispose d'une piste de trésorerie suffisante pour 10 mois sur la base du dernier flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: ACARIX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 16.1 % chaque année

Acarix Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

Recent updates

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.051 loss in 2Q 2023)

Acarix Expands Within US Wellness Exam Market

Acarix AB (publ) announced that it expects to receive SEK 21 million in funding

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study

Acarix AB (Publ) Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024

First quarter 2024 earnings released: kr0.019 loss per share (vs kr0.045 loss in 1Q 2023)

Acarix AB (publ) Approves Board Elections

Acarix AB Announces Initiation of the First Us-Based Clinical Workflow Evaluation Study

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.16 loss per share (vs kr0.31 loss in FY 2022)

Acarix Appoints New Members to the Advisory Board

New major risk - Share price stability

Acarix AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 33.667038 million.

Acarix AB (publ) Announces CEO Changes

Chief Operations Officer recently bought kr157k worth of stock

Acarix AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Acarix AB (publ) Advances the Utilization of Its CADScor System Within the Veterans Administration (Va) Healthcare Network

New major risk - Financial position

Third quarter 2023 earnings released: kr0.038 loss per share (vs kr0.084 loss in 3Q 2022)

Acarix AB (publ) has completed a Composite Units Offering in the amount of SEK 54.344161 million.

Price target increased by 18% to kr0.90

Second quarter 2023 earnings released: kr0.051 loss per share (vs kr0.073 loss in 2Q 2022)

Acarix AB (Publ) Appoints Dr. Deepak R. Talreja Md as New Medical Advisor

Acarix AB Elects Mikael Thorén as Director

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Full year 2022 earnings released: kr0.31 loss per share (vs kr0.37 loss in FY 2021)

Acarix AB (publ) to Report Fiscal Year 2022 Final Results on Apr 20, 2023

Acarix AB (publ) to Report Q4, 2023 Results on Feb 15, 2024

Acarix AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Acarix AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

Acarix AB (publ) Announces Patient Enrollment Completed in the Filter-Scad Randomized Controlled Multi-Center Trial

Second quarter 2022 earnings released: kr0.073 loss per share (vs kr0.093 loss in 2Q 2021)

Acarix AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr2.60

No independent directors

Acarix AB (publ), Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Acarix Submits Breakthrough Designation Request with Food and Drug Administration for Heart Failure Diagnosis

Acarix AB (Publ) Announces CE Approval and FDA Denovo of CADScor System

Third quarter 2021 earnings released: kr0.076 loss per share (vs kr0.11 loss in 3Q 2020)

We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate

Second quarter 2021 earnings released: kr0.093 loss per share (vs kr0.20 loss in 2Q 2020)

Will Acarix (STO:ACARIX) Spend Its Cash Wisely?

Director has left the company

Director has left the company

Director has left the company

Chairman of the Board Werner Braun has left the company

First quarter 2021 earnings released: kr0.083 loss per share (vs kr0.21 loss in 1Q 2020)

Full year 2020 earnings released: kr0.51 loss per share (vs kr1.83 loss in FY 2019)

Director recently bought kr890k worth of stock

Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth

New 90-day low: kr1.12

Acarix AB (publ) Announces Positive Preliminary Data from the Exploratory SEISMO Study

Acarix Receives US Market Approval for the CADScor System

New 90-day high: kr1.29

Acarix AB (Publ) Announces Positive Results from Acarix study presented at ISPOR

Third quarter 2020 earnings released: kr0.11 loss per share

Acarix AB (publ) to Report Q1, 2021 Results on May 11, 2021

New 90-day high: kr1.22

Acarix AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 56.00188 million.

New 90-day low - kr0.73

Acarix AB (publ) to Report Q4, 2020 Results on Feb 18, 2021

Earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan